Next Pharmaceuticals announces positive Flavoxine results

SALINAS, Calif. Next Pharmaceuticals announced Thursday the results of their small-sample clinical trial, which found that its supplement Flavoxine significantly reduced LDL-cholesterol and triglycerides, and also decreased blood pressure and fasting blood glucose.

The study also found that Flavoxine increased HDL-cholesterol, and may be helpful in weight reduction.

“Flavoxine is the result of Next Pharmaceuticals devoting many years to finding a natural formula for heart health that would have multiple benefits,” stated Charles Kosmont, chief executive officer of Next Pharmaceuticals. “We are very satisfied with the results of this study and the benefits Flavoxine will provide to people who prefer a safe and effective natural approach to their heart health.”

The study was recently published in Nutrition Journal, an open access, peer-reviewed, online journal. The published clinical trial is also available at PubMed and archived in PubMed Central.

The 8-week, placebo-controlled study was conducted with four groups, comparing the effects of Flavoxine to placebo in overweight and normal weight. The subjects were given Flavoxine (a combination of two botanical extracts; Phellodendron amurense bark and Citrus sinensis peel) or a matching placebo.

Eighty subjects were enrolled and 45 subjects completed the study.